论文部分内容阅读
前列腺癌生长是由雄激素促发的。基于靶向雄激素受体(androgen receptor,AR)的药物的雄激素剥夺治疗(androgen deprivation therapy,ADT)是治疗转移性前列腺癌患者的常用方法。虽然大多数患者会在开始治疗的时候产生应答,但是癌症几乎总会复发并且变得更具侵袭性。一些癌症通过一种被称作细胞谱系可塑性的机制逃避靶向药物治疗,通过这种机制,肿瘤细胞获得一种存活不再依赖于药物靶标的细胞谱系的表型特征。
Prostate cancer is caused by androgen. Androgen deprivation therapy (ADR), a drug based on androgen receptor (AR), is a common treatment for patients with metastatic prostate cancer. Although most patients will respond at the start of treatment, cancers almost always relapse and become more aggressive. Some cancers escape targeted drug therapy through a mechanism known as cell lineage plasticity by which tumor cells acquire a phenotypic profile of cell lineage that no longer relies on drug targets.